After helping launch two cardiovascular biomarker companies, Lanman was recruited to be Chief Medical Officer of Veracyte, Inc. in 2008, then a seed stage company developing minimally invasive genomics tests to better diagnose thyroid nodules and lung nodules without resorting to surgery.